Federal and state agencies continue to deliver tools and information to help healthcare providers respond to the COVID-19 pandemic since the President declared the COVID-19 outbreak
On March 19, 2020, the FDA revised its guidance on postmarket adverse event reporting for medical products and dietary supplements during a pandemic to apply the guidance to the ongoing COVID-19...
The U.S. Department of Health and Human Services issued a declaration (the “Declaration”) under the Public Readiness and Emergency Preparedness Act (the “PREP Act”) to protect “Covered Persons” ...
The rapid spread of Coronavirus Disease 2019 (COVID-19) has sparked public fear and panic-induced stockpiling of alcohol-based sanitizing gels, leaving retailers and consumers without access to ...
Health Law Vitals - special edition focused on Life Sciences, FDA and COVID-19. Browse a number of featured stories and quick reports on breaking news in this area.
HIPAA Guidance During COVID-19. Amidst continuing COVID-19 concerns, regulators issued certain waivers of HIPAA requirements and penalties as well as additional guidance ap...
As the COVID-19 pandemic surges and the social distancing imperative continues, regulators have responded with various guidelines and policies that impact and expand the opportunities for telehe...
Under Section 1135 of the Social Security Act, the Secretary of the U.S. Department of Health & Human Services (“Secretary”) is authorized to waive or modify certain federal regulatory requirements wh...